Biotech Showcase™ 2016: Interview: Enumeral aspires to take PD-1 inhibition to the next level

February 11, 2016
Enumeral CEO Arthur Tinkelenberg explains his company’s human-driven immune profiling platform and how it could help develop tomorrow’s checkpoint inhibitors to “The Pink Sheet” Senior Writer Emily Hayes. Enumeral’s platform allows researchers to study cells directly from patients, in order to identify those who will respond to particular drugs. In late 2014, the Cambridge, Massachusetts-based biotech secured a collaboration deal with Merck that involves using this platform to interrogate the tumor microenvironment in human colon cancer tissues, for use in predicting response to the big pharma’s immunotherapies. Much research work to date has been in rodent models, but predicting how immunomodulatory therapy works using animal models doesn’t work very well, the exec explains. Tinkelenberg also discusses his company’s lead preclinical candidate, a PD-1 inhibitor for lung cancer that will be aimed at PD-1 treatment failures. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: Cenna puts its own spin on trusted amyloid beta target
Biotech Showcase™ 2016: Interview: Cenna puts its own spin on trusted amyloid beta target

Amyloid beta is a well-established target in Alzheimer’s disease, and yet there have been many failures in ...

Next Video
Biotech Showcase™ 2016: Interview: Renova develops gene therapies for CHF and type 2 diabetes
Biotech Showcase™ 2016: Interview: Renova develops gene therapies for CHF and type 2 diabetes

Renova Therapeutics co-founder and CEO Dr. Jack Reich tells Informa Pharma Insights director of global cont...